Agents noted to produce responses are the same noted to be active in celomic epithelial carcinoma of the ovary. The development of additional information about the nature and management of germ cell cancers and rarer malignant tumors of the ovary as well as fallopian tube cancer will continue to be restricted by the low frequency of these lesions. Most interest centers on the potential for Third, although the efficacy of initial surgical cytoreduction in patients with stage III disease has been accepted on the basis of retrospective analyses, prospective trials are needed to address several important questions. One such study suggests an advantage for interval surgical cytoreduction at the midpoint of a series of chemotherapy courses. Prospective randomized Fourth, efforts continue to investigate the role of new agents in the management of ovarian carcinoma.
Current interest continues to center on further delineation of the role of paclitaxel.
The plethora of new agents with activity in patients who are clinically resistant to the platinum Finally, dose intensity continues to command significant interest. Although uncontrolled studies and anecdotal reports of high-dose chemotherapy with marrow reconstitution appear promising, the highly selected nature of the patients and the expense of the procedures mandate that randomized, comparative trials demonstrate the superiority of this Intraperitoneal administration of drug, although under study for over a decade, still has no defined role in management. In the salvage setting, it appears to have no advantage over intravenous therapy. The final determination of the role, if any, for intraperitoneal therapy awaits the completion of the In conclusion, the future holds the promise of continuing advances in the management of patients with celomic epithelial carcinoma of the ovary.